Edmonton, Alberta, June 5, 2025 – TheNewswire - Visionstate Corp. (TSXV: VIS) is pleased to announce the official launch of MIRA, its newest software-as-a-service (SaaS) platform designed to streamline and digitize inspections across public-facing facilities. The platform became available to customers in June 2025 following months of development and testing in real-world conditions. MIRA represents the latest evolution in Visionstate’s commitment to delivering smart, scalable, and data-driven tools for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to _______________ Commission file number 001-41765 MIRA Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Florida 85-3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________ Commission file number 001-31361 MIRA Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Florida 85-3354547 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class: Trading symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share MIRA The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class: Trading symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share MIRA The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ ...

Mira Pharmaceuticals (NASDAQ:MIRA) stock is down on Tuesday as the clinical-stage pharmaceutical company's shares come off of a major rally on Monday. Shares of MIRA stock closed out Monday's normal trading hours up 627.4%. That came alongside heavy trading with more than 153 million shares traded. For comparison, its daily average trading volume is about 3.2 million shares. Mira Pharmaceuticals stock experienced this rally after releasing data from a pre-clinical study of Ketamir-2. This is the company's n ...

Implications for Patient Care and Market Potential: Economic Impact: With the financial burden of treatment-resistant depression alone accounting for $43.8 billion annually in the U.S., Ketamir-2's development could lead to substantial cost savings in healthcare by providing a more efficient and safer treatment alternative. MIRA is on track to submit an IND application for Ketamir-2 to the FDA by the end of this year. This submission will mark a significant milestone in advancing Ketamir-2 toward clinical t ...

Loading... READ THE FULL MIRA RESEARCH REPORT The company announced that it achieved positive preclinical study results for Ketamir-2, its Novel Oral ketamine Analog. The company characterized these results as "highly encouraging" and are as follows, as reported by MIRA: A) Mice treated with Ketamir-2 showed dose-related, significantly greater locomotor activity, higher travel speed and a trend towards an increased time spent in the center of the arena, indicating reduced anxiety levels. A) In this model of ...

The highly encouraging study results further MIRA's goal of submitting an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) later this year which, if granted, would allow for human clinical trials of Ketamir-2. The following findings were observed: "We are thrilled with the promising results from these preclinical trials, which demonstrate Ketamir-2's efficacy and improved safety profile over traditional ketamine," said Erez Aminov, Chairman & CEO of Mira Pharmaceutic ...

Key Advantages of MIRA-55 Over Marijuana: "We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company. We remain committed to advancing it through the development ...